Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Literature DB >> 16641471

Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Olle Aspevall¹, Annika Lundberg, Lars G Burman, Thomas Akerlund, Bo Svenungsson.

Abstract

All 238 Clostridium difficile isolates were susceptible to metronidazole and vancomycin, whereas 84% and 1% were resistant to clindamycin and fusidic acid. Etest MICs for metronidazole were lower than agar dilution MICs (P < 0.01) but without difference in susceptible-intermediate-resistant categorization. No particular PCR ribotype was associated with clindamycin or fusidic acid resistance.

Entities: Chemical Species

Mesh：

Substances：

Year: 2006 PMID： 16641471 PMCID： PMC1472208 DOI： 10.1128/AAC.50.5.1890-1892.2006

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

29 in total

1. Reduced susceptibility of Clostridium difficile to metronidazole.

Authors: J S Brazier; W Fawley; J Freeman; M H Wilcox
Journal: J Antimicrob Chemother Date: 2001-11 Impact factor: 5.790

2. Metronidazole resistance in Clostridium difficile.

Authors: S Johnson; J L Sanchez; D N Gerding
Journal: Clin Infect Dis Date: 2000-08 Impact factor: 9.079

Review 3. Epidemiology of nosocomial clostridium difficile diarrhoea.

Authors: M H Samore
Journal: J Hosp Infect Date: 1999-12 Impact factor: 3.926

4. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile.

Authors: I Poilane; P Cruaud; J C Torlotin; A Collignon
Journal: Clin Microbiol Infect Date: 2000-03 Impact factor: 8.067

5. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors: Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal: Lancet Date: 2005 Sep 24-30 Impact factor: 79.321

6. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study.

Authors: J Wiström; S R Norrby; E B Myhre; S Eriksson; G Granström; L Lagergren; G Englund; C E Nord; B Svenungsson
Journal: J Antimicrob Chemother Date: 2001-01 Impact factor: 5.790

7. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

Authors: F Barbut; D Decré; B Burghoffer; D Lesage; F Delisle; V Lalande; M Delmée; V Avesani; N Sano; C Coudert; J C Petit
Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191

8. Fusidic acid disk diffusion testing of clostridium difficile can be calibrated using single-strain regression analysis.

Authors: M Oppenheimer; G Kronvall; I Karlsson; E Holst
Journal: Scand J Infect Dis Date: 2000

9. Clostridium difficile cytotoxin B in adults with diarrhea: a comparison of patients treated or not treated with antibiotics prior to infection.

Authors: B Svenungsson; A Lundberg
Journal: Clin Microbiol Infect Date: 2001-08 Impact factor: 8.067

10. Clindamycin resistant strains of Clostridium difficile isolated from cases of C. difficile associated diarrhea (CDAD) in a hospital in Sweden.

Authors: Torbjorn Norén; Yajarayma J Tang-Feldman; Stuart H Cohen; Joseph Silva; Per Olcén
Journal: Diagn Microbiol Infect Dis Date: 2002-02 Impact factor: 2.803

15 in total

Review 1. Epidemiology, pathogenesis, and management of Clostridium difficile infection.

Authors: Rajaraman Durai
Journal: Dig Dis Sci Date: 2007-04-03 Impact factor: 3.199

2. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.

Authors: Kevin A Brown; Nagham Khanafer; Nick Daneman; David N Fisman
Journal: Antimicrob Agents Chemother Date: 2013-03-11 Impact factor: 5.191

Review 3. Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors: Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal: World J Gastrointest Pharmacol Ther Date: 2014-02-06

4. Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.

Authors: Kenneth F Blount; Cynthia Megyola; Mark Plummer; David Osterman; Tim O'Connell; Paul Aristoff; Cheryl Quinn; R Alan Chrusciel; Toni J Poel; Heinrich J Schostarez; Catherine A Stewart; Daniel P Walker; Peter G M Wuts; Ronald R Breaker
Journal: Antimicrob Agents Chemother Date: 2015-07-13 Impact factor: 5.191

5. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.

Authors: Annie-Claude Labbé; Louise Poirier; Duncan Maccannell; Thomas Louie; Michel Savoie; Claire Béliveau; Michel Laverdière; Jacques Pépin
Journal: Antimicrob Agents Chemother Date: 2008-06-23 Impact factor: 5.191

6. Molecular epidemiology of Clostridium difficile strains from nosocomial-acquired infections.

Authors: Silvia Corbellini; Giorgio Piccinelli; Maria Antonia De Francesco; Giuseppe Ravizzola; Carlo Bonfanti
Journal: Folia Microbiol (Praha) Date: 2013-10-01 Impact factor: 2.099

7. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.

Authors: Harsh Mathur; Paula M O'Connor; Colin Hill; Paul D Cotter; R Paul Ross
Journal: Antimicrob Agents Chemother Date: 2013-04-09 Impact factor: 5.191